Italian pharmacy online: cialis senza ricetta medica in farmacia.
Sri Adichunchanagiri College of Pharmacy
Department of Clinical Pharmacy, Adichunchanagiri Hospital & Research Centre, B.G.Nagara, Karnataka- 571448
, email@example.com; Phone: 08234 287055 Ext: 250; 08234 287590 (SACCP)
DRUG INFOS- Online Drug Information Center; 08234-290234, firstname.lastname@example.org
Dr. B Ramesh, Dr. Rajesh Venkataraman, Mr. B.P Satish Kumar, Mr. M Kumaraswamy, Dr. Rajveer Singh Chopra
Sri Adichunchanagiri College of Pharmacy is the premier educational institution in Pharmaceutical Sciences. The institution is under the aegis of Sri Adichunchanagiri Shikshana Trust under the leadership of Sri Sri Sri Nirmalanandanatha Swamiji. Now the institution is offering; D.Pharm, B.Pharm, M. Pharm, Pharm D and Pharm D (Post Baccalaureate) courses, approved by AICTE, PCI & Affiliated to RGUHS Bangalore.
Grape Juice Mixed With Some Prescription Drugs Can
Eating grapefruit can be dangerous for people taking
amlodipine, apixaban, cilostazol, clopidogrel,
certain prescription medications, but many doctors are
dronedarone, elerenone, ergotamine, Felodipine,
unaware of the risks. The Lawson Health Research
losartan, manidipine, nicardipine, nifedipine, nimodipine,
Institute in London, Canada has studied the effects of
nisoldipine, nitrendipine, propafenone, quinidine,
mixing grapefruit juice with prescription drugs for
rivaroxaban, sibutramine, sildenafil, tadalafil, ticagrelor,
decades. As recently as 2008, they had a list totaling 17
vardenafil, aprepitant, alfentanil-oral, buspirone,
medications that shouldn't be taken with the juice. Their
carbamazepine, dextromethorphan, diazepam, fentanyl-
current findings have now upped that number to 44
oral, fluvoxamine, ketamine-oral, lurasidone, methadone,
drugs. Experts explain that certain medications react
midazolam,-oral, oxycodone, pimozide, quazepam,
adversely to grapefruit juice by processing in your body at
quetiapine, sertraline, triazolam, ziprasidone, estradiol,
a faster rate. While this may sound harmless, researchers
ethinylestradiol, cisapride, domperidone, cyclosporine,
say it actually creates a significant increase in the drug's
everolimus, sirolimus, tacrolimus, darifenacin,
potency. In some cases, the strength of certain medicines
festerodine, solifenacin, silodosin, tamsulosin.
can be raised to a point equivalent to the patient getting double the dose with each pill.Here are the drugs that
The research team also said the effects of combining
researchers said should not be taken with grapefruit juice:
grapefruit juice with certain medications varies in severity, so patients taking one of the listed drugs should speak to
Crizotinib, cyclophosphamide, dasatinib, erlotinib,
their doctor about the specific effects of their particular
everrolimus, imatinib, lapatinib, nilotinib, pazopanib,
medicine. The study also showed that some drugs
sorafenib, sunitinib, vandetanib, venurafenib,
increase in potency with the citrusy juice, while other
repaglinide, saxagliptin, albendazole, artemether,
drugs are weakened. In addition, the combination of the
erythromycin, etravirine, halofantrine, maraviroc,
juice with certain medicines can bring about skin rashes,
praziquantel, primaquine, quinine, rilpivirine, saquinivir,
dizziness, headaches, breathing troubles and a number
budesonide-oral, colchicine, methylprednisolone-oral,
atorvastatin, lovastatin, simvastatin, amiodarone,
We acknowledge, the Doctors of Adichunchanagiri Hospital and Research Center for
their constant support.
FDA Drug Safety Communication: Risk of next-morning impairment
after use of insomnia drugs
FDA is notifying the public of new information about
Zolpidem is a sedative-hypnotic (sleep)
zolpidem, a widely prescribed insomnia drug. FDA
medicine used in adults for the treatment of insomnia.
recommends that the bedtime dose be lowered because
RECOMMENDATION: FDA urges health care professionals
new data show that blood levels in some patients may be
to caution all patients (men and women) who use these
high enough the morning after use to impair activities that
products about the risks of next-morning impairment for
require alertness, including driving. This announcement
activities that require complete mental alertness, including
focuses on zolpidem products approved for bedtime use.
Women appear to be more susceptible to this risk because they eliminate zolpidem from their bodies more slowly than
• The recommended dose of zolpidem for women should
be lowered from 10 mg to 5 mg for immediate-release
products and from 12.5 mg to 6.25 mg for extended-
Because use of lower doses of zolpidem will result in lower
blood levels in the morning, FDA is requiring the
• For zolpidem and other insomnia drugs, prescribe the
manufacturers of Ambien, Ambien CR, Edluar, and Zolpimist
lowest dose that treats the patient's symptoms.
• Inform patients that impairment from sleep drugs can be
FDA is continuing to evaluate the risk of impaired mental
present despite feeling fully awake.
alertness with other insomnia drugs, including over-the-counter (OTC) drugs available without a prescription.
FDA Pushing to Eliminate Most Prescriptions; Make Majority of Drugs
The FDA is considering a new prescription program also
Although the FDA has not yet decided how to expand access
referred to as the "New Paradigm" that would enable certain
of certain prescription medications, one key element of their
prescription drugs to be available without a prescription if
proposal surrounds a pharmacist-driven patient care
they met certain criteria that ensured "conditions of safe use."
program that would likely involve patient counseling, patient
The program would involve a variety of medications that treat
monitoring, drug interaction prevention and simple
so-called "common conditions" (i.e. hypertension, diabetes,
diagnostic testing. Another element of the proposal,
elevated cholesterol, migraine headaches, asthma, flu,
suggested by the FDA, may involve having a physician
allergies, smoking cessation etc.) The FDA's apparent
prepare the initial prescription for the medication with
rationale behind this proposal is based on evidence from the
subsequent access to the medication without a prescription
National Journal that shows that people in the U.S. have poor
if "conditions of safe use" are met. Lastly, the FDA believes
medication adherence due to a variety of factors (i.e. costs,
various technologies like pharmacy-based kiosks or internet
time, need for multiple physician visits, lack of a prescription
based questionnaires may help support their proposal by
drug plan and so on) that ultimately hamper the prescription
helping patients properly self-diagnose and select the
and medication renewal processes. In addition, the FDA
appropriate medication(s) for their condition(s).
believes that these factors dissuade a person from taking potentially lifesaving medications which further contributes to the under-treatment of common medical condition.
Chemicals Found In Bee Stings Could Help Prevent The Spread of HIV
Scientists at Washington University School of Medicine in St.
rampant spread of HIV, which causes AIDS.
Louis believe that chemicals found in bee stings can destroy the virus, preventing it from becoming AIDS. According to
The bees' chemical, melittin, destroys the HIV virus by
the Midwestern school's doctors the nanoparticles carrying
puncturing its protective outer layer. Scientists inserted the
the toxin -- called melittin -- destroys HIV, while leaving
toxin into tiny nano particles, which are fitted with special
“bumpers” so they can off normal cells. But when the smaller HIV virus makes contact with them, it slips between the
Scientists are excited by the find and believe it could be an
bumpers and is attacked by the toxin.
important step towards developing a gel to stem the
NEW DRUG PROFILE – ALOGLIPTIN
is 25/2000mg. It comes as a tablet to take by mouth
This medication is an anti-diabetic drug, prescribed for
(1.2.5/500mg), two times per day with food.
Warnings and Precautions :
* Caution should be
exercised in patients with history of liver impairment, acute
Contraindicated in patients with kidney impairment,
pancreatitis, any allergy, who are taking other medications,
metabolic acidosis, diabetic ketoacidosis, and
elderly, children, during pregnancy and breastfeeding.
* Patient may develop with increased risk of liver failure (sometimes fatal); monitor liver functions and complete
blood counts regularly while taking this medication.
Category B : Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate
Mechanism of Action
and well-controlled studies in pregnant women OR Animal
Alogliptin is a small-molecule, orally available dipeptidyl
studies have shown an adverse effect, but adequate and
peptidase IV (DPP IV) inhibitor. DPP-4 inhibitors slow the
well-controlled studies in pregnant women have failed to
inactivation of incretin hormones GLP-1 (glucagon-like
demonstrate a risk to the fetus in any trimester.
peptide-1) and GIP (glucose-dependent insulinotropic peptide), both of which play a role in regulating blood
Dosage & When it is to be taken: PO - The initial dose is
based on patient's condition. Maximum recommended dose
DRUGS APPROVED BY CDSCO DURING Jan - Mar 2013
Name of Drug
Date of issue
Diclofenac Diethylamine BP 2.32 % w/v Eq to
Diclofenac Sodium 2.00 % w/v + Methyl Salicylate IP
10.00% w/v + Menthol 5.00 % w/v + Absolute Alcohol IP 10.00 % v/v Topical Solution (Additional Strength)
Telmisartan 20mg + Amlodipine Besylate Eq. to
Amlodipine 2.5mg + Hydrochlorothizide 6.25mg
Amlodipine besilate IP Eq. to Amlodipine 10mg +
Indapamide SR 1.5 mg Ta b l e t ( A d d i t i o n a l
For the treatment of patients with myelofibrosis including primary myelofibrosis, post-polycythemia
v e r a m y e l o f i b r o s i s o r p o s t- e s s e n t i a l t h r o m b o c y t h e m i a myelofibrosis.
“We strive in serving the Medical fraternity”
ACTIVITIES DURING JAN - MAR 2013
Total Online Drug Informations Given: 45
No. of Queries
Online Drug Information Centre (ODIC)
was inaugurated on 24th January 2013 by
the Department of Pharmacy Practice in association with Adichunchanagiri Hospital &
Research Center, B.G.Nagara. The programme Inaugurated by Dr. T.M Manohar,
Medical Superintendent, AH&RC continued with welcome note by Dr. B.Ramesh,
Principal, SACCP.A talk on “Need for Drug Infos – Current Scenario” by
Mr.Samson.P.George, Drug Information Pharmacist, Drug Information Centre KSPC,
Karnataka. Intorduction to ODIC by Dr.Rajesh.V, Associate Professor & Head,
Department of Pharmacy Practice and Manager Drug Infos.
Following Eminent Personalities specialized in the field of Pharmacy Practice professionalized the one day work shop organized by the college on “Core Values of Clinical Pharmacist in Health Care”.
Dr. M.S.Ganachari, Professor & Head, Department of Pharmacy Practice, KLE’S College of Pharmacy, Belgaum
Dr. B.J.Mahendra Kumar, Professor & Head Department of Pharmacy Practice, JDT Islam College of Pharmacy, Kerela
Dr. P.K.Manna, Professor of Pharmacy, Annamalai University, Tamil Nadu
Dr. Anand B. Harugeri , Patient Safety Manager, Astra Zeneca Pharma India Ltd.
Dr. Geeta Kishore, Professor & Head, Department of Pharmacy Practice, KIMS, Bangalore
Dr. Shobha Rani R H, Professor & Head, Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bangalore.
Sri Adichunchanagiri College of Pharmacy
B.G Nagara - 571448, Karnataka.
Ph : 08234-287870, 287590 (Telefax)
Mob: +91 9845863779 (Principal)
e-mail : email@example.com
GENERIC NAMELetrozole tablet 2.5mgCHEMICAL NAME4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrileDOSAGE FORM: Each Film coated tablet containsLetrozole 2.5mg Tablet. CATEGORYAnticancer Drugs, Aromatase inhibitorsPHARMACOLOGICAL CLASSIFICATIONLetromina™ is an oral nonsteroidal aromatase inhibitor for adjuvant treatment of hormonally responsive breast cancer. Estrogens are produced by the conv
EXAMINING THE BOOK OF ESTHER Part One: ESTHER, THE QUEEN OF PURIM, A TALMUDIC TALE OF TERROR AND TREACHERY By Dr. Harrell Rhome ©2011 All Rights Reserved. The curious Book of Esther, one of only two in the Bible not mentioning God, may have been composed BCE485-464 during the reign of King Ahasueris, roughly concurrent with the reign of Xerxes I in Persia. The names c